➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Express Scripts
McKesson
Boehringer Ingelheim
Harvard Business School
Medtronic
Dow

Last Updated: August 6, 2020

DrugPatentWatch Database Preview

Romiplostim - Biologic Drug Details

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for romiplostim
Tradenames:1
Patents:24
Applicants:1
BLAs:1
Suppliers: see list1
Recent Clinical Trials: See clinical trials for romiplostim
Recent Clinical Trials for romiplostim

Identify potential brand extensions & biosimilar entrants

SponsorPhase
Seoul National University HospitalPhase 2
Peking Union Medical College HospitalPhase 2/Phase 3
Kyowa Hakko Kirin Korea Co., Ltd.Phase 2

See all romiplostim clinical trials

Pharmacology for romiplostim

Company Disclosures: US Patents for romiplostim

These patents were extracted from company disclosures
Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Amgen NPLATE romiplostim INJECTABLE; SUBCUTANEOUS 125268 001 2008-08-22   Start Trial Amgen Inc. (Thousand Oaks, CA) 2018-10-23 RX Orphan company
Amgen NPLATE romiplostim INJECTABLE; SUBCUTANEOUS 125268 001 2008-08-22   Start Trial Amgen Inc. (Thousand Oaks, CA) 2018-10-23 RX Orphan company
Amgen NPLATE romiplostim INJECTABLE; SUBCUTANEOUS 125268 001 2008-08-22   Start Trial Amgen Inc. (Thousand Oaks, CA) 2018-10-23 RX Orphan company
Amgen NPLATE romiplostim INJECTABLE; SUBCUTANEOUS 125268 001 2008-08-22   Start Trial Amgen Inc. (Thousand Oaks, CA) 2018-10-23 RX Orphan company
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Patent Text Search: US Patents for romiplostim

These patents were identified by searching patent claims

Supplementary Protection Certificates for romiplostim

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
6 Finland   Start Trial
09/022 Ireland   Start Trial PRODUCT NAME: ROMIPLOSTIM; REGISTRATION NO/DATE: EU/1/08/497/001-002 20090204
598 Luxembourg   Start Trial PRODUCT NAME: ROMIPLOSTIM (NPLATE - ROMIPLOSTIM)
/2009 Austria   Start Trial PRODUCT NAME: ROMIPLOSTIM; REGISTRATION NO/DATE: EU/1/08/497/001-002 20090204
2009 00025 Denmark   Start Trial
2009 009 Romania   Start Trial PRODUCT NAME: NPLATE-ROMIPLOSTIM; NATIONAL AUTHORISATION NUMBER: RO EU/1/08/497/001, RO EU/1/08/497/002; DATE OF NATIONAL AUTHORISATION: 20090204; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EMEA EU/1/08/497/001, EMEA EU/1/08/497/002; DATE OF FIRST AUTHORISATION IN EEA: 20090204
1124961/01 Switzerland   Start Trial FORMER REPRESENTATIVE: BOHEST AG, CH
>Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Moodys
McKesson
Dow
Merck
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.